DMII (Drugs Made In America Acquisition II) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)


DMII Drugs Made In America Acquisition II Corp DMII
15 GF Score
Price $10.10
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition II 3-Year EBITDA Growth Rate?

Drugs Made In America Acquisition II DMII 15 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates DMII with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 204 Diversified Financial Services companies, Drugs Made In America Acquisition II ranks worse than 490195.59% on this metric.

Drugs Made In America Acquisition II's EBITDA per Share for the three months ended in Mar. 2026 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Drugs Made In America Acquisition II  (NAS:DMII) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Drugs Made In America Acquisition II 3-Year EBITDA Growth Rate Related Terms

DMII vs BCSS, EVAC, CEPF: 3-Year EBITDA Growth Rate Comparison

For the Shell Companies subindustry, Drugs Made In America Acquisition II's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Drugs Made In America Acquisition II 3-Year EBITDA Growth Rate vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition II's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Drugs Made In America Acquisition II's 3-Year EBITDA Growth Rate falls into.


DMII
15GF Score
Drugs Made In America Acquisition II Corp DMII
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Drugs Made In America Acquisition II 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Drugs Made In America Acquisition II (DMII) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Drugs Made In America Acquisition II and its competitors. According to the industry distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 204 companies in the Diversified Financial Services industry.
Is Drugs Made In America Acquisition II's 3-Year EBITDA Growth Rate too high?
Drugs Made In America Acquisition II's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 204 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's 3-Year EBITDA Growth Rate compare to BCSS and EVAC?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 204 companies for 3-Year EBITDA Growth Rate. This places Drugs Made In America Acquisition II in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 18.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Diversified Financial Services company?
The median 3-Year EBITDA Growth Rate among Diversified Financial Services companies is 18.45, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Drugs Made In America Acquisition II and its competitors. For the Diversified Financial Services industry, the median 3-Year EBITDA Growth Rate is 18.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drugs Made In America Acquisition II's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition II Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition II Corp is a blank check Company.
15GF Score

Get the complete analysis for DMII

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.10
Price